Replay available

Immunic, Inc. (IMUX) Q4 2023 Earnings Call

Immunic, Inc. (NASDAQ: IMUX) Q4 2023 earnings conference call, held 2024-02-22. Replay captured from the company's public earnings webcast.

Thu, February 22, 2024 at 8:00 AMendedReplay
Immunic, Inc.  (IMUX) Q4 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Yungo Kwak

Analyst, Piper Sandler & Co.

Matt Kaplan

Analyst, Ladenburg Thalmann

Jessica Bru

Vice President, Investor Relations and Communications

Nat Ransom

Analyst, Leerink Partners

Dr. Daniel Fitt

Chief Executive Officer and President

Glenn Whaley

Chief Financial Officer

William Wood

Analyst, B. Riley Securities

Caroline Pocher

Analyst, Wedbush Securities

Replay transcript excerpt

Good morning to everybody on the line. I would like to welcome you to Immunix's fourth quarter and year-end 2023 earnings call. My name is Jessica Bru, Vice President Investor Relations and Communications at Immunix. I will also be the moderator today. Speaking on the call are Dr. Daniel Fitt, our Chief Executive Officer and President, as well as Glenn Whaley, our Chief Financial Officer. Please note that all participants will be in listen-only mode, and this event is being recorded. After today's presentation, there will be an opportunity to ask questions. If you joined the webcast via the Zoom platform, there are two ways to submit questions. You can either submit your questions in writing via the Q&A tool of the Zoom portal, or if you would like to speak with us directly, please use the raise hand function in the Zoom portal to queue your question. Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with a similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunex's actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunix's opinions only as of the date of this presentation and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunix's SEC filings for a more detailed description of the risk factors that may affect Immunix's results and these forward-looking statements. I would now like to turn the call over to our CEO and President, Dr. Daniel Fitt, to begin the p...

More from Immunic, Inc.